In this study, we demonstrate that activation of TRKA by its ligand NGF is also potent to elicit a disease with striking similarities to human SM in a mouse model and is involved in the development of resistance to KIT-targeted therapy. This evidence concerns the gene NGF and systemic mastocytosis.